Application of joint detection of AFP, CA19-9, CA125 and CEA in identification and diagnosis of cholangiocarcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 8, 2015, Pages 3451-3455

  Li, Yong ^a   Li, Da Jiang ^a   Chen, Jian ^a   Liu, Wei ^a   Li, Jian Wei ^a   Jiang, Peng ^a   Zhao, Xin ^a   Guo, Fei ^a   Li, Xiao Wu ^a   Wang, Shu Guang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; Hepatocellular carcinoma; Identification and diagnosis; ROC curve; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; BILE DUCT NEOPLASMS; BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; CHOLANGIOCARCINOMA; FEMALE; HUMAN; INTRAHEPATIC BILE DUCT; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ALPHA-FETOPROTEINS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOMARKERS, TUMOR; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84929008320     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.8.3451     Document Type: Article

References (23)

1. Al-Bahrani R, Nagamori S, Leng R, et al (2015). Differential Expression of Sonic Hedgehog Protein in Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Pathol Oncol Res, Epub ahead of print.
2. Asayama Y, Nishie A, Ishigami K, et al (2015). Distinguishing intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma using precontrast and gadoxetic acid-enhanced MRI. Diagn Interv Radiol, 21, 96-104.
3. Charatcharoenwitthaya P, Enders FB, Halling KC, et al (2008). Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology, 48, 1106-17.
4. Chaiteerakij R, Harmsen WS2, Marrero CR, et al (2014). A new clinically based staging system for perihilar cholangiocarcinoma. Am J Gastroenterol, 109, 1881-90.
5. Dai XZ, Yin HT, Sun LF, et al (2013). Potential therapeutic efficacy of curcumin in liver cancer. Asian Pac J Cancer Prev, 14, 3855-9.
6. Hemming AW, Reed AI, Fujita SMP, et al (2005). Surgical management of hilar cholangiocarcinoma. Ann Surg, 241, 693-702.
7. Kim SW, Lim do H, Park HC, et al (2015). Salvage radiation therapy for isolated local recurrence of extrahepatic cholangiocarcinoma after radical surgery: a retrospective study. Ann Surg Oncol, 22, 1308-14.
8. Liu Y, Qian HX, Zhuo M, et al (2013). Influences of Resveratrol on the Proliferation of Cholangiocarcinoma Cells and Expression of p21 and p27 Proteins. J Int Transl Med, 1, 201-4.
9. Lumachi F, Lo Re G, Tozzoli R, et al (2014). Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study. Anticancer Res, 34, 6663-7.
10. Liu LK, Shao MW, Ma L, et al (2015). Values of seven tumor markers in identification and diagnosis of esophageal carcinoma accompanied by neuroendocrine differentiation. J Int Transl Med, 3, 541-5.
11. Mohammad-Alizadeh AH, Ghobakhlou M, Shalmani HM, et al (2012). Cholangiocarcinoma: an-eight-year experience in a tertiary-center in Iran. Asian Pac J Cancer Prev, 13, 5381-4.
12. Nakeeb A, Lipsett PA, Lillemoe KD, et al (1996). Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg, 171, 147-53.
13. Nanashima A, Sumida Y, Abo T, et al (2007). Patient outcome and prognostic factors in intrahepatic cholangiocarcinoma after hepatectomy. Hepatogastroenterology, 54, 2337-42.
14. Patel AH, Harnois DM, Klee GG, et al (2000). The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol, 95, 204-7.
15. Qu K, Liu SN, Chang HL, et al (2012). Gallbladder cancer: a subtype of biliary tract cancer which is a current challenge in China. Asian Pac J Cancer Prev, 13, 1317-20.
16. Sheen-Chen SM, Sun CK, Liu YW, et al (2007). Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci, 52, 3140-2.
17. Sheen-Chen SM, Sun CK, Liu YW, et al (2007). Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci, 52, 3140-2.
18. Shao L, Hong W, Zhang YP (2013). Survival model established by combined serum tumor markers in predicating the effect of erlotinib on patients with recurrent non-small Cell Lung Cancer. J Int Transl Med, 1, 185-93.
19. Taketa K, Okada S, Win N, et al (2002). Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar. Acta Med Okayama, 56, 317-20.
20. Tang X, Zhang J, Chen Y, et al (2014). Correlation between clinicopathological features and CA19-9/CEA in patients with extrahepatic cholangiocarcinoma. Chin J Oncol, 36, 662-6.
21. Tyson GL, Ilyas JA, Duan Z, et al (2014). Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. Dig Dis Sci, 59, 3103-10.
22. Xu C, Lv PH, Huang XE, et al (2014). Safety and efficacy of sequential transcatheter arterial chemoembolization and portal vein embolization prior to major hepatectomy for patients with HCC. Asian Pac J Cancer Prev, 15, 703-6.
23. Zuckerman E, Lanir A, Sabo E, et al (1999). Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol, 94, 1613-8.